Pacira Pharmaceuticals Inc., of Parsippany, N.J., said that its Phase III trial of Exparel for pain control post-hemorrhoidectomy met its primary endpoint of reducing pain and opioid use in the first 72 hours. Results were presented in a poster at the 2011 American Society of Colon and Rectal Surgeons annual meeting in Vancouver, British Columbia.